By Carrie Chen
HONG KONG (Nov 02) -- Shanghai Fosun Pharmaceutical (Group), a company controlled by Chinese conglomerate Fosun International, said a unit has agreed to acquire the 69.25% stake it doesn't already own in Taiwan-based biopharmaceutical company Henlix Biotech for up to $98 million.
The company's unit Shanghai Henlius will buy out other corporate and individual shareholders and make Henlix a wholly-owned subsidiary, Fosun Pharma said in a filing to the Hong Kong stock exchange on Thursday.
The agreement is subject to approvals from authorities in Taiwan and China.
- By Carrie Chen; Carrie.Chen@NikkeiNewsrise.com; +852 39605153
- Edited By V.Phani Kumar
- Send Feedback to feedback@NikkeiNewsRise.com
- Copyright (c) 2017 Nikkei NewsRise Asia Pte Ltd.